Yuan Liu

Yuan Liu

Auto-generated profile, based on publicly available information

Yuan Liu

MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of medicine, Jiangnan University, China (S.Y., Z.W., T.Y., Y.L., F.Y., A.M., L.F., X.W., X.M.).

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
KZKa Zhang
Ka Zhang
YLYuan Liu
Yuan Liu
AMAiqin Mao
Aiqin Mao
CLChangzhu Li
Changzhu Li
LGLi Geng
Li Geng
HKHao Kan
Hao Kan
Background: The proteome is a key source of therapeutic targets. We conducted a comprehensive Mendelian randomization analysis across the proteome to identify potential protein markers and therapeutic targets for abdominal aortic aneurysm (AAA). Methods and Results: Our study used plasma proteomics data from the UK Biobank, comprising 2923 proteins from 54 219 individuals, and from deCODE Genetics, which measured 4907 proteins across 35 559 individuals. Significant proteomic quantitative trait loci were used as instruments for Mendelian randomization. Genetic associations with AAA were sourced from the AAAgen consortium, a large‐scale genome‐wide association study meta‐analysis involving 37 214 cases and 1 086 107 controls, and the FinnGen study, which included 3869 cases and 381 977 controls. Sequential analyses of colocalization and summary‐data‐based Mendelian randomization were performed to verify the causal roles of candidate proteins. Additionally, single‐cell expression analysis, protein–protein interaction network analysis, pathway enrichment analysis, and druggability assessments were conducted to identify cell types with enriched expression and prioritize potential therapeutic targets. The proteome‐wide Mendelian randomization analysis identified 34 proteins associated with AAA risk. Among them, 2 proteins, COL6A3 and PRKD2, were highlighted by colocalization analysis, summary‐data‐based Mendelian randomization, and the heterogeneity in an independent instrument test, providing the most convincing evidence. These protein‐coding genes are primarily expressed in macrophages, smooth muscle cells, and mast cells within abdominal aortic aneurysm tissue. Several causal proteins are involved in pathways regulating lipid metabolism, immune responses, and extracellular matrix organization. Nine proteins have already been targeted for drug development in diabetes and other cardiovascular diseases, presenting opportunities for repurposing as AAA therapeutic targets. Conclusions: This study identifies causal proteins for AAA, enhancing our understanding of its molecular cause and advancing the development of therapeutics.

19 June 2026 in Circulation Research
Verified
Journal Article
Closed access
SYShaying Yang
Shaying Yang
ZWZhiwei Wang
Zhiwei Wang
TYTeng Yang
Teng Yang
YLYuan Liu
Yuan Liu
FYFan Yu
Fan Yu
XMXin Ma
Xin Ma
BACKGROUND: Dysfunction of endothelial cells manifests early in pulmonary arterial hypertension and represents a critical therapeutic target. Nevertheless, the limited efficacy of single-target interventions underscores the need for innovative strategies that enable precise therapeutic modulation. METHODS: The TRPV4 (transient receptor potential vanilloid 4)-KCa2.3 (small-conductance calcium-activated potassium channel 3) interaction was validated in experimental pulmonary hypertension mice using co-immunoprecipitation and fluorescence (Förster) resonance energy transfer. Based on structure-guided molecular docking, a small-molecule candidate, JNc-455, was rationally designed. RESULTS: Dissociation of the TRPV4-KCa2.3 complex was confirmed by both co-immunoprecipitation and fluorescence (Förster) resonance energy transfer analyses in lung tissues from patients with pulmonary arterial hypertension and experimental pulmonary hypertension mice. Endothelial cell-specific recombinant adeno-associated virus-mediated disruption of the complex promoted both the initiation and progression of pulmonary hypertension in vivo. Guided by these findings, we developed a series of compounds aimed at restoring TRPV4-KCa2.3 coupling. Among them, JNc-455 demonstrated significant therapeutic efficacy without overt toxicity. However, this effect was absent in endothelial TRPV4-deficient mice (TRPV4 EC −/− ), indicating that the action of JNc-455 critically depends on the structural integrity of the complex. CONCLUSIONS: This study investigates the critical role of the TRPV4-KCa2.3 complex in pulmonary arterial hypertension and, based on these findings, facilitates drug development and screening, thereby identifying JNc-455 as a promising novel therapeutic candidate for pulmonary arterial hypertension.